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BES SES OR 95% CI
Deﬁnite stent thrombosis
0-3 years 17 (1.4%) 12 (1.0%) 1.45 (0.69-3.13)
0-1 year 10 (0.8%) 3 (0.2%) 3.41 (1.04-15.3)
1-2 years 6 (0.5%) 3 (0.2%) 2.16 (0.57-10.3)
2-3 years 1 (0.1%) 6 (0.5%) 0.17 (0.01-0.98)
Very late stent thrombosis 7 (0.6%) 9 (0.7%) 0.81 (0.29-2.19)
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Background: There is limited head-to-head data on long-term safety and efﬁcacy
outcomes for everolimus-eluting stent (EES) and sirolimus-eluting stent (SES).
Methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with
Clinical Outcome) IV trial we prospectively randomized 2,774 patients. The SORT
OUT IV trial demonstrated non-inferiority of the EES to the SES at 9 months. Follow-
up through 5 years was complete in 2,770 (99.9%)). The 5-year pre-speciﬁed endpoint
was a composite of safety and efﬁcacy (major adverse cardiac event (MACE): cardiac
death, myocardial infarction, target vessel revascularization and deﬁnite stent
thrombosis).
Results: At 4-year EES remained non-inferior to SES for the composite primary end
point which occurred in 11.8% in the EES group and in 14.7% in the SES group
(hazard ratio (HR) 0.80, 95% conﬁdence interval (CI) 0.65-0.98). Cardiac death 3.8%
vs. 3.9% (HR 0.98, 95% CI 0.67-1.43) did not differ between the two groups, whereas
target lesion revascularization (EES 4.2% vs. SES 6.2%, (HR 0.68, 95% CI 0.49-0.95)
and myocardial infarction (EES 2.9% vs. SES 4.3%, (HR 0.67, 95% CI 0.45-1.00).
Deﬁnite stent thrombosis were lower in the EES group (0.3%) compared to the SES
group (2.0%) (HR¼0.15, 95% CI 0.05-0.45) which largely was attributable to a lower
risk of very late deﬁnite stent thrombosis: 0.1% versus 1.3% (HR¼0.11, 95% CI 0.03-
0.47). The 5-year results will be available for presentation at the TCT meeting 2014.
Conclusions: At 4-year follow-up, MACE rate was signiﬁcantly lower in EES treated
patients compared to SES. The 5-year results will be available for presentation at the
TCT meeting 2014.
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Background: Drug-eluting stents with biodegradable polymers have been developed
to address the risk of very late adverse events such as stent thrombosis. The purpose of
this analysis was to compare incidence of stent thrombosis in an all-comers percu-
taneous coronary intervention (PCI) cohort treated with the biodegradable polymer-
coated biolimus-eluting stent (Nobori; BES) or the durable polymer-coated
everolimus-eluting stent (Xience or Promus; EES).
Methods: The COMPARE II study is an open-label, prospective, randomized, non-
inferiority, all-comer trial undertaken at 12 sites across Europe currently at 3-year
follow-up. Patients were randomly allocated (2:1) to receive either a BES or EES.
Stent thrombosis was deﬁned according to the Academic Research Consortium.
Results: Of the 2707 study patients (4025 lesions), 2683 (99.1 %) completed 3 years
follow-up. The 3-year stent thrombosis rates in the BES and EES group are tabulated.Events at 3 years
EES
(n¼912)
BES
(n¼1795)
Relative Risk
[95% CI] p-value
Deﬁnite Stent Thrombosis
All Stent Thrombosis 0.8% (7) 1.2% (21) 1.52 [0.65-3.57] 0.33
Early Stent Thrombosis 0.3% (3) 0.6% (11) 1.86 [0.52-6.66] 0.33
Late Stent Thrombosis 0.1% (1) 0.1% (2) 1.02 [0.09-
11.19]
0.99
Very Late Stent
Thrombosis
0.3% (3) 0.5% (8) 1.36 [0.36-5.09] 0.65
Deﬁnite or Probable Stent Thrombosis
All Stent Thrombosis 1.4% (13) 1.3% (23) 0.90 [0.46-1.77] 0.76
Early Stent Thrombosis 0.8% (7) 0.6% (11) 0.80 [0.31-2.05] 0.64
Late Stent Thrombosis 0.2% (2) 0.2% (3) 0.76 [0.13-4.55] 0.77
Very Late Stent
Thrombosis
0.4% (4) 0.5% (9) 1.14 [0.35-3.70] 0.82
JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteConclusions: At 3-year follow-up the biodegradable polymer-coated BES has similar
stent thrombosis rates as the durable polymer-coated EES without observing any
tendency for reduction in frequency of this event beyond 1 year. In comparison to
second-generation durable polymer coated DES, these results challenge the concept of
biodegradable polymers.
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Background: There is limited head-to-head data on late stent-related outcomes for
biolimus-eluting biodegradable (BES) polymer-coated Nobori stent and durable
polymer-coated sirolimus-eluting stent (SES).
Methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with
Clinical Outcome) V trial we prospectively randomized 2468 patients. The SORT
OUT V trial did not demonstrate non-inferiority of the BES to the SES at 9 months.
Follow-up through 3 years is complete in 2467 (99.96%). The 3-year pre-speciﬁed
endpoint was a composite of safety and efﬁcacy (MACE: cardiac death, myocardial
infarction and target vessel revascularization and deﬁnite stent thrombosis) and the
safety endpoint of interest was deﬁnite stent thrombosis.
Results: At 3-year MACE rate did not differ signiﬁcantly between the two groups:
BES group (10.1%) compared to the SES group (11.2%) (hazard ratio (OR) 0.90, 95%
conﬁdence interval (CI) 0.69-1.16). Deﬁnite stent thrombosis occurred within 3 years
in 30 patients (1.2%). Overall rate of deﬁnite stent thrombosis did not differ signiﬁcant
between BES or SES treated patients (1.4% versus 1.0%, (OR¼1.33, 95% CI
0.64-2.81)).Conclusions: At 3-year follow-up the Nobori stent with a biodegradable polymer was
not associated with a lower risk of MACE or deﬁnite stent thrombosis compared to the
Cypher stent with a durable polymer. However, the risk of stent thrombosis was time-
dependent. In the ﬁrst year the risk was higher in the Nobori group. In the period from
2 to 3 year after implantation the risk was lower in the Nobori group
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Background: Drug-eluting stents with biodegradable polymers have been developed
to reduce the risk of very late adverse events such as stent thrombosis. Recent studies
have indicated similar results with regard to safety outcomes for the biodegradable
polymer-coated biolimus-eluting stent (Nobori; BES) compared to the durable
polymer-coated everolimus-eluting stent (Xience or Promus; EES) at 1 year.
However, these trials were not powered to detect differences in low-frequency events
such as stent thrombosis.
Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned
5942 patients to BES or EES and is at present the largest pooled analysis of BES in
all-comers requiring percutaneous coronary intervention (PCI). Here we conducted a
patient level analysis at 1 year to assess rates of stent thrombosis deﬁned according to
the Academic Research Consortium.
Results: The pooled unadjusted 1-year stent thrombosis rates of the 5942 study pa-
tients (8094 lesions) are tabulated. Covariate adjusted analyses accounting for baselinents - Drug-Eluting: Stent Thrombosis B187
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comimbalances between trials conﬁrmed non-signiﬁcant differences between stent type
and stent thrombosis rates. The trend for a higher deﬁnite stent thrombosis rate in the
BES group was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60];
p¼0.16).
Conclusions: At 1-year follow-up the biodegradable polymer-coated BES has similar
stent thrombosis rates as the durable polymer-coated EES. However, incidence of
deﬁnite stent thrombosis is numerically higher in the BES group without reaching
statistical signiﬁcance. Longer follow-up is needed to determine the safety proﬁle of
biodegradable polymer-coated BES in real world clinical practice.Events at 1 years
EES BES
p-value(n¼2,530) (n¼3,412)
Deﬁnite Stent Thrombosis
All Stent Thrombosis 0.2% (5) 0.5% (17) 0.08
Early Stent Thrombosis 0.2% (4) 0.4% (13) 0.14
Late Stent Thrombosis 0.04% (1) 0.1% (4) 0.40
Deﬁnite or Probable Stent Thrombosis
All Stent Thrombosis 0.4% (10) 0.5% (18) 0.57
Early Stent Thrombosis 0.3% (8) 0.4% (13) 0.83
Late Stent Thrombosis 0.1% (2) 0.2% (5) 0.71TCT-645
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Background: Bioresorbable scaffolds (BVS) are a new treatment for coronary artery
disease with promising results in ﬁrst-in-man studies. As their use is extending in more
complex lesions and populations, several cases of BVS thrombosis have been re-
ported. We present optical coherence tomography ﬁndings from the culprit lesion of
patients with BVS thrombosis.
Methods: Up to 1/5/2014, 442 patients received BVS in our center. Among those, 14
patients that developed deﬁnite BVS thrombosis, according to the ARC criteria, were
readmitted to our cathlab. Eight of them were imaged by optical coherence tomog-
raphy (OCT) at the time of the event. OCT images were reviewed ofﬂine and the
presence of thrombus, underexpansion, neointimal hyperplasia >50%, incomplete
scaffold apposition, and scaffold discontinuity were assessed. The current status of
dual antiplatelet therapy at the time of the event was also recorded.
Results: Thrombus was visualized in 7/8 cases, underexpansion in 1/8, neointimal
hyperplasia >50% in 2/8, incomplete scaffold apposition in 4/8, and scaffold
discontinuity in 2/8 cases. In 3 cases, dual antiplatelet therapy had been discontinued
at the time of the event. A summary of the most prominent OCT ﬁndings is presented
in the Table.Case
Type/
timing Baseline OCT ﬁndings Prominent OCT ﬁndings at event
Dual
antiplatelet
therapy
1 Acute/
same day
Thrombus at proximal stent edge,
deriving from an adjacent
ﬁbroatheroma
Yes
2 Subacute/
2 days
Thrombus overlying extensive overlap
region (7.6mm)
Yes
3 Late/
40 days
Undersizing/residual
thrombus/plaque
prolapse
Incomplete scaffold apposition with
thrombus
Yes
4 Late/
4 months
Occlusive edge restenosis Yes
5 Late/
4 months
Uncovered struts at the carina of a
bifurcation treated with T-stenting
No
6 Late/
4 months
Scaffold fracture Thrombus overlying overlap region
with underexpansion/ scaffold
fracture
No
7 Late/
7 months
Incomplete scaffold apposition/
occlusive restenosis
Yes
8 Very late/
2 years
Optimal scaffold
expansion
Late scaffold discontinuity/
incomplete scaffold apposition
No
B188 JACC Vol 64/11/Suppl B j SeptemberConclusions: Discontinuation of antiplatelet therapy was identiﬁed in some patients
as a reason for BVS thrombosis, however, in the majority of the cases mechanical
factors were identiﬁed by OCT as a substrate. OCT can provide useful insights on the
pathomechanisms of this complication.
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Background: Incidence of late stent thrombosis (ST) is increasing due to the persistent
risk of thrombosis after implantation. Most of the cases are treated with percutaneous
coronary intervention (PCI). PCI of late-ST with additional stent implantation has been
associated with worse outcomes. Intravascular ultrasound (IVUS) imaging is able to
assess the pathological causes of late-ST and guide the best treatment. The objectives of
this study are to describe the IVUS ﬁndings of late-ST and compare outcomes between
patients treated without and with additional stent implantation.
Methods: All patients with late-ST (>1 month) undergoing IVUS-guided PCI were
included in 7 Spanish institutions. The operators were left to decide the PCI treatment:
balloon angioplasty (POBA) vs. stent implantation. Four IVUS ﬁndings were
assessed: late incomplete stent apposition (LISA), aneurysm, stent underexpansion
and excessive neointimal proliferation.
Results: 117 patients were included (54.4% drug-eluting stents). The median time
after implantation was 3.5 years. ST was presented as ST-elevation myocardial
infarction in 99 (84.1%) patients. Additional stent implantation was used in 54 patients
(46.2%). Prior to intervention, there were no differences in LISA (71.4% vs. 63.0%;
p¼0.33), aneurysm (11.1% vs. 11.1%; p¼1.0), underexpansion (31.7% vs. 18.5%;
p¼0.10) or excessive neointimal proliferation (11.1% vs. 22.2%; p¼0.10) between
patients treated with POBA vs. additional stent implantation. After PCI, persistent
LISA was observed in 25.4% vs. 51.9% of patients (p¼0.01), respectively. Persistent
underexpansion was observed in 6.3% and 14.8% (p¼0.05). Follow-up was obtained
at 2.0 years. Cardiac death was observed in 3.4% vs. 5.8% of patients treated without
and with additional stent (p¼0.55). Deﬁnite or probable re-thrombosis was observed
in 1.7% vs. 7.7% (p¼0.13), respectively.
Conclusions: The most frequent IVUS ﬁndings of late-ST are LISA and under-
expansion. POBA seems to improve these IVUS-ﬁndings with respect to additional
stent implantation. IVUS-guided treatment of deﬁnite ST is associated with favorable
outcomes independently of the use of additional stent implantation.
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Background: Stent thrombosis (ST) has been described as a rare event in current
drug-eluting stent (DES) era; however, its occurrence has been associated with high
morbimortality, including fatality rates up to 50%. Previous studies have shown ST
could be increased in complex subsets; however, the incidence and predictors of ST
after DES overtime are still no fully understood
Methods: A total of 5,408 pts with >8,000 coronary lesions undergoing routine or
emergency PCI were prospectively (and consecutively) enrolled in the DESIRE
(Drug-Eluting Stent In the REal World) registry at single institution between May/
2002 and May/2012 (enrollment ongoing). By protocol, clinical follow-up was per-
formed at 1 and 6 months, and yearly up to 12 years post-index procedure (97%).
Stent thrombosis (ST) was deﬁned according to the propositions of the Academic
Research Consortium.
Results:Mean age was 65 years, 32% had diabetes, and 16% had clinical presentation
of recent myocardial infarction (MI) (< 30 days). Overall, patients were treated with
approximately 8,500 DES and angiographic success was high (>99%) despite rela-
tively high complexity in the majority of lesions (67% type B2/C). Up to 12 years
(median 4.9 years) FU, cumulative incidence of ST was 2.4%, given that 95.1% of
patients were ST-free at 10 years (Kaplan-Meier survival curve). Of the 113 ST re-
ported, 13% occured up to 30 days, 55% were deﬁnite ST (ARC), and >60% occured
12 months. Independent predictors of ST are shown in the Table.13–17, 2014 j TCT Abstracts/Stents - Drug-Eluting: Stent Thrombosis
